Cepadacursen sodium - CiVi Biopharma
Alternative Names: CIVI-007; CiVi007Latest Information Update: 28 Mar 2021
At a glance
- Originator Santaris Pharma
- Developer CiVi Biopharma; Roche
- Class Antihyperlipidaemics; Antisense oligonucleotides; Cardiovascular therapies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Hypercholesterolaemia in United Kingdom (SC, Injection)
- 28 Jan 2021 CiVi Biopharma completes a phase II trial in Hypercholesterolaemia in USA (SC) (NCT04164888)
- 30 Sep 2020 Civi Biopharma completes a phase-I trials in Hypercholesterolaemia in United Kingdom (SC) (NCT03427710)